Abstract | BACKGROUND: PATIENTS AND METHODS: 34 patients were selected and randomly divided into 2 groups to receive either intermittent or continuous oral alfacalcidol. Baseline data were obtained on serum calcium, phosphorus, alkaline phosphatase and PTH. All but the PTH were monitored monthly. PTH levels were measured again until the end of the protocol. The intervention was 2 microg of alfacalcidol given after each dialysis session (intermittent group) or 1 microg given 6 days/week (continuous group). RESULTS: Serum calcium and phosphorus showed a tendency to increase from baseline levels in both groups. Mean PTH levels for both groups showed a progressive reduction over time during the study period. This decrement showed no significant difference with regard to the schedule of alfacalcidol administration when comparing the 2 groups. There also was no difference in the incidence of side effects-- hypercalcemia and hyperphosphatemia--between the intermittent and continuous intervention. CONCLUSION:
|
Authors | F Tarrass, A Yazidi, H Sif, M Zamd, M G Benghanem, B Ramdani |
Journal | Clinical nephrology
(Clin Nephrol)
Vol. 65
Issue 6
Pg. 415-8
(Jun 2006)
ISSN: 0301-0430 [Print] Germany |
PMID | 16792136
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Hydroxycholecalciferols
- PTH protein, human
- Parathyroid Hormone
- Phosphorus
- Alkaline Phosphatase
- Calcium
- alfacalcidol
|
Topics |
- Administration, Oral
- Adult
- Alkaline Phosphatase
(blood)
- Calcium
(blood)
- Drug Administration Schedule
- Female
- Humans
- Hydroxycholecalciferols
(administration & dosage, therapeutic use)
- Hyperparathyroidism
(complications, drug therapy)
- Hyperparathyroidism, Secondary
(drug therapy)
- Kidney Failure, Chronic
(complications)
- Male
- Middle Aged
- Parathyroid Hormone
(blood)
- Phosphorus
(blood)
- Renal Dialysis
(methods)
|